Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Cardiff Oncology (CRDF) over the last 14 years, with Q3 2025 value amounting to 0.98%.

  • Cardiff Oncology's Return on Capital Employed fell 800.0% to 0.98% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.98%, marking a year-over-year decrease of 800.0%. This contributed to the annual value of 0.64% for FY2024, which is 1300.0% down from last year.
  • Cardiff Oncology's Return on Capital Employed amounted to 0.98% in Q3 2025, which was down 800.0% from 0.85% recorded in Q2 2025.
  • In the past 5 years, Cardiff Oncology's Return on Capital Employed ranged from a high of 0.16% in Q1 2021 and a low of 0.98% during Q3 2025
  • For the 5-year period, Cardiff Oncology's Return on Capital Employed averaged around 0.5%, with its median value being 0.46% (2023).
  • As far as peak fluctuations go, Cardiff Oncology's Return on Capital Employed surged by 20600bps in 2021, and later plummeted by -3600bps in 2024.
  • Over the past 5 years, Cardiff Oncology's Return on Capital Employed (Quarter) stood at 0.21% in 2021, then crashed by -71bps to 0.36% in 2022, then plummeted by -71bps to 0.61% in 2023, then decreased by -20bps to 0.73% in 2024, then crashed by -34bps to 0.98% in 2025.
  • Its last three reported values are 0.98% in Q3 2025, 0.85% for Q2 2025, and 0.67% during Q1 2025.